CellFiber Opens US Subsidiary in Philadelphia to Accelerate Scalable Manufacturing of iPSC, MSC, and CAR-T Cell Therapies

URLhttps://firstwordpharma.com/story/8194956
SourceFirst Word Pharma
Date Published10/09/2026

Additional Reshoring Information:

Company/Division name CellFiber
Parent companyCellFiber Co., Ltd.
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2026
Domestically, the work will be done:In-house
Country(ies) from which reshored:Japan
City reshored to:Philedelphia
State(s) reshored to:PA
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshored3D cell culture, bioprocessing for pharma
What non-domestic negative factors made offshoring less attractive?Supply chain interruption
What domestic positive factors made reshoring more attractive?3D Printing/Additive Manufacturing, Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training
Find Reshoring Articles